Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Up 118.4% in May

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large growth in short interest in May. As of May 29th, there was short interest totaling 1,228,229 shares, a growth of 118.4% from the May 14th total of 562,363 shares. Based on an average daily volume of 44,575,019 shares, the days-to-cover ratio is currently 0.0 days. Approximately 2.7% of the company’s stock are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Liminatus Pharma has an average rating of “Sell”.

Liminatus Pharma Price Performance

Shares of NASDAQ:LIMN opened at $0.12 on Friday. The company’s fifty day moving average price is $0.18 and its 200 day moving average price is $0.47. Liminatus Pharma has a 12 month low of $0.12 and a 12 month high of $33.66. The firm has a market capitalization of $5.48 million and a P/E ratio of -0.28.

Liminatus Pharma (NASDAQ:LIMN) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.03) EPS for the quarter.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.